Hernández-Guillén Á, Alfaro-Moya T, Fernández-Morales H

Idioma: Español
Referencias bibliográficas: 18
Paginas: 61-66
Archivo PDF: 164.20 Kb.

RESUMEN

foramen oval permeable es un defecto cardiaco que se puede encontrar en pacientes jóvenes con evento cerebrovascular criptogénico. Este también representa una de las posibles causas de cortocircuito derecha-izquierda en el embolismo paradójico, en asociación con trombosis venosa periférica y una condición hemodinámica efectiva por embolismo. Presentamos el caso de un paciente de 41 años que desarrolla múltiples eventos isquémicos y un síndrome de enclaustramiento en el contexto de un foramen oval permeable y trombosis venosa profunda.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Amarenco P, Bogousslavsky J, Caplan LR, et al. The ASCOD Phenotyping of Ischemic Stroke (Updated ASCO Phenotyping). Cerebrovasc Dis 2013; 36: 1–5

2. d’Audiffret A, Shenoy SS, Ricotta JJ, Dryjski M. The role of thrombolytic therapy in the management of paradoxical embolism. Cardiovasc Surg. 1998; 6: 302e306

3. Guzik A, Bushnel C. Stroke Epidemiology and Risk Factor Management. Continuum (Minneap Minn) 2017; 23(1): 15–39

4. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984; 59: 17-20

5. Handke M, Harloff A, Olschewski M. Patent Foramen Ovale and Cryptogenic Stroke in Older Patients. N Engl J Med 2007; 357: 2262 8

6. Khan AR, Abdulhak AAB, Sheikh MA, et al. Device Closure of Patent Foramen Ovale Versus Medical Therapy in Cryptogenic Stroke: A Systematic Review and Meta-Analysis. J Am Coll Cardiol Intv 2013; 6:1316–23

7. Kissela BM, Khoury JC, Alwell K, et al. Age at stroke: Temporal trends in stroke incidence in a large, biracial population.. Neurology 2012; 79: 1781–1787

8. Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: the defense-pfo trial. J Am Coll Cardiol 2018; 71: 2335–42

9. Maaijwee NAMM, Rutten-Jacobs LCA, Schaapsmeerders P, et al. Ischaemic stroke in young adults: risk factors and long-term consequences. Nat. Rev. Neurol. 2014; 10: 315–325

10. Mas JL, Derumeaux G, Guillon B, et al; CLOSE Investigators. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017; 377: 1011–1021

11. Miranda B, Fonseca AC, Ferro JM. Patent foramen ovale and stroke. J Neurol 2018. https://doi.org/10.1007/s00415-018-8865-0

12. Montessuit M, Pretre R, Bruschweiler I, Faidutti B. Screening for patent foramen ovale and prevention of paradoxical embolus. Ann Vasc Surg 1997; 11(2): 168e72

13. Saver JL, Mattle HP, Thaler D. Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Ischemic Stroke: A Topical Review. Stroke. 2018; 49: 1541-1548

14. Singhal AB, Biller J, Elkind MS, et al. Recognition and management of stroke in young adults and adolescents. Neurology 2013; 81: 1089–1097

15. Søndergaard L, Kasner SE, Rhodes JF, et al; Gore REDUCE Clinical Study Investigators. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017; 377:1033–1042

16. Thompson T, Evans W. Paradoxical embolism. QJM: An International Journal of Medicine 1930; 23: 135–50

17. Torrealba-Acosta G, Carazo-Céspedes K, Chiou SH, et al. Epidemiology of Stroke in Costa Rica: A 7-Year Hospital-Based Acute Stroke Registry of 1319 Consecutive Patients. Journal of Stroke and Cerebrovascular Diseases. 2017. Https://doi.org/10.1016/j.jstrokecerebrovasdis. 2017.11.030

18. Windecker S, Stortecky S, Meier B. Paradoxical Embolism. Journal of the American College of Cardiology. 2014; 64(4): 403-415